BioWin

Primary tabs

Printer-friendly versionPrinter-friendly version
General Information
The date when the cluster organisation was established: 
Sunday, 1 January, 2006
Number of staff in the management team of the cluster organisation : 
6-10
Legal form of the cluster organisation: 
Non-Profit
Regions: 
Prov. Hainaut
Cluster Excellence Label: 
Bronze Label
Membership to European Strategic Cluster Partnerships (ESCP-4i or ESCP-S3): 
MAGIA
S3martMed
Membership to other networks/partnerships: 
NameWebsite
EDCA European Diagnostic Cluster Alliance - Presidence
http://www.edc-alliance.eu/
CEBR Council of European BioRegions - Presidence
http://www.lifescience-cluster-innovations.space/
Rad4Med.be The Belgian network for Radiation Applications in Healthcare
http://rad4med.be/
European Biotech Network
http://european-biotechnology.net/
Cluster Management Team: 
NameSurnamePositionTelephoneEmail
Sylvie
Ponchaut
Cluster Manager
+3271919285
international@biowin.org
Link to team description on the cluster's website: 
http://www.biowin.org/biowin/en/5573-the-team.html
Languages spoken: 
Dutch
English
French
Sectoral and Industrial Focus
Sectoral Industries: 
Biopharmaceuticals
Technology fields: 
Medical Technology / Biomedical Engineering
Pharmaceutical Products / Drugs
S3 EU priority areas: 
e-Health (e.g. healthy ageing)
Advanced manufacturing systems
Emerging industries: 
Biopharmaceuticals
Digital Industries
Areas of specialisation of the cluster not covered above: 
(1) Radiation applications to Healthcare (2) Immunology & Vaccines (3) Cell therapy and regenerative medicine (4) Biomanufacturing (5) Diagnostics
Composition of the cluster
Total number of members: 
550
Number of SME members: 
157
Number of start-ups among SME members: 
1
Number of larger company members: 
7
Number of research organisations/universities/technology centres: 
400
Link to the cluster members’ list: 
http://www.biowin.org/biowin/en/5469-members-directory.html
Entrepreneurship and scale-up support facilities in the cluster's ecosystem (see "Organisation type"): 
Name and link of major players: 
NameWebsiteType
GSK
http://be.gsk.com/
Larger Company
UCB
http://www.ucb.com/worldwide/belgium-luxembourg
Larger Company
Baxter
http://www.baxter.be/fr/
Larger Company
IBA
http://www.iba-worldwide.com/
Larger Company
IRE
http://www.ire.eu/en
Larger Company
Eurogentec
http://www.eurogentec.com/eu-home.html
Larger Company
Zoetis
https://www.zoetis.com/
Larger Company
Cluster Strategy
Mission/Objectives: 

Created in July 2006, BioWin is the reference player in the field of health biotechnology and medical technologies in Wallonia (a region located South Brussels, in Belgium). The cluster federates all the Walloon stakeholders (companies, research centers and universities) involved in innovative R&D projects and/or trainings for the development of new products and services:

BioWin has defined 4 strategic development axis aimed to support Wallonia's academic and industrial excellence in the health sector but also to take upon the challenges raised by an emerging industry with:

  • Calls for R&D projects.
  • International visibility and partnering/networking activities.
  • Tailor-made training programs which are specific to the needs of bioindustry.
  • The support to the creation of collective infrastructures and technological platforms.
Do you have a formalised strategy?: 
Yes
Do you have a specific strategy focus that addresses internationalisation ?: 
Yes
Services
Support services provided: 
Access to the European Internal market
Access to public support (regional/national programmes, innovation vouchers, etc.)
Facilitation of collaboration between members
Enabling Facilities sharing
Provision and facilitation of access to training for members
Details of support services: 

BioWin has defined four strategic areas of development that are key to achieving its aims.Foster the emergence of innovative R&D projects in human and animal health  The Government of Wallonia initiates regional and international calls for R&D projects to encourage a collaborative dynamic between universities, companies and research centres so that together, they develop innovative products and services with high added-value and potential for commercialization at the national and international level. BioWin supports 7 technological domains through its smart specialisation strategy. Check our complete S3 strategy online: http://www.biowin.org/biowin/en/8468-key-sectors-in-wallonia.html​Globally promote and position Walloon expertise Develop communication tools aimed to promote scientific and industrial excellence from Wallonia on the world stage by participating in the main Healthcare biotechnology trade fairs, by creating and consolidating partnerships and/or relationships with foreign competitiveness clusters and Healthcare clusters, and by participating in European networks and projects.Develop skills, attract and retain a highly qualified human capital Implement training programmes to ensure the availability of a qualified and skilled workforce to support the development of the healthcare and biotechnology sectors, both in the short term and in years to come.Support the creation of collective technological infrastructures Support the emergence of innovation platforms capable of meeting the collective technological needs of the members.

Cooperation Activities
International Cooperation
The main countries targeted by the cluster organisation: 
Canada
China
Israel
United States
Our cluster organisation undertook the following international activities to support our members: 
Participation at missions/events/study visits/fairs
Trans-national Cooperation
The main countries targeted by the cluster organisation: 
France
Germany
Luxembourg
Netherlands
United Kingdom
Our cluster organisation undertook the following trans-national activities to support our members: 
Support to collaborative activities/etc.
Which clusters do you collaborate with?: 
Atlanpole Biotherapies, France
Alsace BioValley, France
BioAlps, Suisse
Bio-Pro, Germany
BioTop, Berlin, Germany
Eurobiomed, France
Lyonbiopole, France
Medicen, France
CQDM - Consortium Québécois du Médicament (Québec, Canada)
MLSC - Massachusetts Life Sciences Center (USA)
Support Programmes
Participation in Funded Support Programmes: 
European ProgrammesProject Name
FP7
CIP/COSME
INTERREG

Magia - COSME Cluster Go international project  - 2018-2020

BioWin is member of COSME Cluster Go international project "Magia" in the medical technologies sector (MedTech) i.e. medical devices, In Vitro Diagnostics and medical imaging equipment. The initiative shall support MedTech sector especially SMEs and business network organisations to intensify collaboration across borders with four industrial clusters: Bioindustry Silvano Fumero (Italy), BioWin (Belgium), Lyonbiopole (France) and Norgenta Nordeutsche (Germany). The ultimate goal of the project is to develop and implement joint strategies to strengthen, through cooperation and resource-sharing, the competitiveness on 2 target global markets of clusters’ SMEs operating in the field and to make the innovative European medtech industry more visible.

ABC Europe (CIP – Europe Innova - DG Entreprise) - 2009-2012

This project is essentially aimed at promoting transnational cooperation between European Health clusters to develop and implement useful tools to increase the international dimension of the clusters and their SME members.It brings together 13 Health clusters : Milan Chamber of Commerce and Industry (IT – Coordinator) – One Nucleus (GB) – Stockholm Science City (SE) – Medicon Valley Alliance (DK-SE) – BioWin (BE) – Medicen (FR) – Alsace Biovalley (FR) - Heidelberg (DE) – BioM (DE)- Cluster BioPMed (IT) – Innova (HU) – El Parc Cientific de Barcelona (SP) – Matimop (IS).

Tissue Engineering and Regenerative Medicine – TERM (Regions of Knowledge – DG Research) - 2010-2013

The “Regions of Knowledge” projects specifically bring together “triple helix” clusters, that is clusters driven by a culture of applied innovation through partnerships between industries and university and non-university research centres and supported by their regional authorities. Clusters and public authorities play an active role in the project to ensure that it is a priority for the region. The initial aim of TERM is to establish a consensus between 13 partners from 7 European regions about a research agenda and non-R&D priorities in the field of regenerative medicine. The partners will then implement these priorities by means of tools that they will develop together (action plan). Partners: Atlanpole Biothérapies (FR - Coordinator) - MedCoast Scandinavia (NO/SE) - Fondazione Centro San Raffaele del Monte Tabor (IT) - UppsalaBIO (SE) - BioWin (BE) - Madrid BioCluster (ES) - Baltic Innovation Agency (EE) - Berlin – Brandenburg Centre for Regenerative Therapies (DE) - Interface Europe (BE) - Région Pays de la Loire (FR) - Service public de Wallonie (BE) - Vinnova (SE) - Uppsala Regional Council (SE).

Nanocardio - INTERREG project - 2016 to 2020

Nanocardio project aims to develop systems for the early diagnosis of atherosclerosis and the risks resulting from it. The project is based on the development of nanoplatforms carrying magnetic and optical diagnostic probes, respectively for magnetic resonance imaging (MRI) and optical imaging (fluorescence). These nanoplatforms will also have a specific system for the recognition of cells from atheromatous plaques. The objective, therefore, is the early detection of atheromatous plaques in order to evaluate the cardiovascular risk for the patient. Nanocardio is a 4 years for a total budget of € 1.6 million.

Partners: University of Mons (Belgium) is the project leader, and the other two operators are the University of Reims (France) and the University of Ghent (Belgium). BioWin is an associated partner of the project, together with IMEC (Leuven, Belgium), Eurasanté (Lille, France), The Institute of Electronics, Microelecrtonics and Nanotechnologies (Villeneuve d’Ascq, France) and the Centre Hospitalier Universitaire of Reims (Reims, France). Main deliverables expected (for BioWin): (1) Support and improve cross-border collaboration in research and innovation (2) Strengthen medical imaging in Wallonia, as well as scientific excellence in one of our clinical and academic assets: the cardiovascular research (3) Opportunity to create connections with new actors that could contribute to the development of BioWin and the Regional Healthcare Ecosystem.

 

 

 
Promotion
Success Story / Achievements: 

Collaborative R&D projects

  • 253 partners,
  • 44 R&D projects
  • creation of 5 companies
  • Total private & public funding of EUR 142 Mios
  • Support the development of 3 technological platforms (cell therapy, proton therapy, big data) and a biobanking network

Skills development

  • 17 granted training projects for a total of EUR 29,6 million
  • Specific trainings followed by 15.000 people to develop technical, scientific and managerial skills to support the growth and competitiveness of the sector.
  • A one-stop shopping platform including continuous trainings in Wallonia for the Health sector. Advisory support from the Skills Development Department

Europe

  • Co-founder different regional/european thematic networks: Wal-Dx (Wallonia in vitro Diagnostics network), Rad4Med.be (Belgian Network for Radiation Applications to Healthcare), EDCA (European Diagnostic Clusters Alliance)
  • Chairmanship of CEBR (Council of European BioRegions) and EDCA
  • Collaborative agreement with Alsace Biovalley – 1 R&D project

Asia and USA

  • Collaborative agreement with CQDM (Canada), MLSC (Massachussets, USA) – 3 transnational projects funded 
  • Partnership with Juke Biotech Park (China)
Why should partners choose you for cooperation?: 

- Integration of innovation players thanks to BioWin activities

- Professionalism of the services provided by BioWin

- Quality and dynamism of the ecosystem

- Excellence in academic and clinical research

- Technological diversity of the industrial players

- Proximity with European authorities

- Strong support of regional authorities